Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension

The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers

(2009) Gennyne Walker et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities

(2008) Michael D. McGoon et al.   CHEST

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

(2008) Nazzareno Galiè et al.   CIRCULATION

Ambrisentan for the management of pulmonary arterial hypertension

(2008) Judy W.M. Cheng   CLINICAL THERAPEUTICS

Pharmacokinetics and Safety of Ambrisentan in Combination With Sildenafil in Healthy Volunteers

(2008) Rebecca Spence et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

(2007) N S Kirkby et al.   BRITISH JOURNAL OF PHARMACOLOGY